Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.
Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.
复制标题
年龄、种族、性别和既往感染状况对单剂BNT 162 b2 mRNA COVID-19疫苗免疫原性的影响：来自以色列医护人员的真实世界证据，2020年12月至2021年1月。
DOI：
10.2807/1560-7917.es.2021.26.6.2100096
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Edelstein M
中科院分区：
文献类型：
--
作者：
Abu Jabal K;Ben-Amram H;Beiruti K;Batheesh Y;Sussan C;Zarka S;Edelstein M
BNT 162 b2 mRNA COVID-19疫苗在临床试验中显示出很高的疗效，但需要来自未纳入试验的人群的观察数据。我们按年龄、种族、性别和既往COVID-19感染描述了514名以色列医护人员在第1次给药后21天的免疫原性。不同种族和性别的免疫原性相似，但随年龄增长而降低。无论接种前是否存在可检测的IgG抗体，既往感染者的抗体滴度均比未感染者高一个数量级。
The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.